Want to see HK:2575 full AI Analyst Report?
2575 Stock Chart & Stats
HK$12.95
--
Market closed
HK$12.95
--
Day’s Range― - ―
52-Week RangeHK$10.25 - HK$96.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
HK$9.24B
Enterprise ValueHK$6.24K
Total Cash (Recent Filing)HK$216.62M
Total Debt (Recent Filing)HK$1.37M
Price to Earnings (P/E)―
Beta2.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding517,947,800
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)23.93
Price to Sales (P/S)650.34
P/FCF Ratio-163.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ScalingSharp revenue expansion indicates meaningful commercial progress and growing product adoption. If sustained, this larger revenue base can improve operating leverage and support the company’s transition toward a more viable specialty-pharmaceutical business.
Improving Gross MarginsThe move to positive gross margin is an important sign that product economics are improving. Continued margin gains could strengthen the path to sustainable profitability, although operating expenses still prevent the benefit from reaching the bottom line.
Conservative Balance SheetLow leverage reduces financial risk and preserves flexibility to fund research, commercialization and operations. Growth in equity and assets also provides a stronger capital base, helping the company pursue expansion while limiting near-term balance-sheet strain.
Bears Say
Persistent Operating LossesPersistent operating and net losses show that revenue growth has not yet produced sustainable earnings. The company must achieve further scale or control costs before its improving gross margin can translate into durable profitability and shareholder returns.
Ongoing Negative Cash FlowRepeatedly negative operating and free cash flow indicates that the business is not yet self-funding. Although burn improved in 2025, continued funding needs raise execution risk and could constrain investment if profitability or cash conversion takes longer than expected.
Negative Returns On EquityConsistently negative return on equity means the company’s capital base is not yet generating shareholder value. This reflects the impact of ongoing losses and makes improved profitability, capital efficiency and cash generation essential for a durable investment case.
Xuanzhu Biopharmaceutical Co., Ltd. Class H News
2575 FAQ
What was Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Xuanzhu Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$10.25 and its highest was HK$96.90 in the past 12 months.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap is HK$9.24B.
When is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xuanzhu Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Xuanzhu Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Xuanzhu Biopharmaceutical Co., Ltd. Class H pay dividends?
Xuanzhu Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xuanzhu Biopharmaceutical Co., Ltd. Class H have?
Xuanzhu Biopharmaceutical Co., Ltd. Class H has 517,947,800 shares outstanding.
What happened to Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xuanzhu Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xuanzhu Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
53.19%
Trailing 12-Months
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. Class H
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―